Gestational diabetes mellitus (GDM) is a prevalent pregnancy complication characterized by glucose intolerance, leading to significant maternal and fetal health risks. Traditional diagnostic methods, primarily glucose tolerance tests, often fail to capture the complex metabolic alterations associated with GDM. Metabolomics, the comprehensive study of small molecules (metabolites) within biological systems, offers a powerful approach to understanding the metabolic disturbances in GDM. Recent research has identified distinct metabolomic profiles, including alterations in amino acid, lipid, and carbohydrate metabolism, that are linked to GDM pathophysiology. These insights open new avenues for personalized medicine, where treatment strategies can be tailored to individual metabolic profiles, improving outcomes and reducing risks. Personalized approaches in GDM could involve enhanced risk prediction, targeted interventions, and real-time monitoring of treatment efficacy, eventually guided by metabolomic data. Thus, the convergence of metabolomics and personalized medicine holds the promise of transforming GDM care, offering more precise and effective strategies for managing this complex condition, and ultimately improving maternal and neonatal health outcomes.